Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company